-
Mashup Score: 2Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion - 9 day(s) ago
With recent prospective clinical trials that used paediatric regimens with multiple doses of pegylated form of asparaginase (PEG asparaginase) in adults reporting significantly improved survival compared with historical data with regimens that used less …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion - 9 day(s) ago
With recent prospective clinical trials that used paediatric regimens with multiple doses of pegylated form of asparaginase (PEG asparaginase) in adults reporting significantly improved survival compared with historical data with regimens that used less …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant - 23 day(s) ago
Bone Marrow Transplantation – EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation - 23 day(s) ago
Bone Marrow Transplantation – Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0A prognostic score system in adult T‐cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation - 23 day(s) ago
Bone Marrow Transplantation – A prognostic score system in adult T‐cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Efficiency of Biomarker-Driven Clinical Trial Designs - 2 month(s) ago
Precision medicine involves biomarker-directed therapeutic strategies that optimize the risk-benefit ratio for each patient. Implementation of precision medicine requires biomarker-driven randomized clinical trials (RCTs) to generate reliable evidence-based assessment of all rel evant components of these biomarker-directed strategies. The increasing number of potential biomarker subgroups and the corresponding smaller number of patients in each subgroup create feasibility challenges for these designs.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 - 2 month(s) ago
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with acute myeloid leukemia (AML) harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. METHODS Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. RESULTS Three hundred fifty-six participants were randomly assigned post-
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0How I treat adult T-cell leukemia/lymphoma - 2 month(s) ago
Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive T-cell malignancy that arises in a proportion of individuals who are long-term carriers of…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Thread by @rajshekharucms on Thread Reader App - 3 month(s) ago
@rajshekharucms: Imp. paper by @VincentRK 𝑒𝑡 𝑎𝑙 on mode of progression in a 𝐦𝐨𝐝𝐞𝐫𝐧 𝐜𝐨𝐡𝐨𝐫𝐭 of patients with smoldering #myeloma! Helpful for initial discussion in patients with 𝐇𝐢𝐠𝐡-𝐑𝐢𝐬𝐤 𝐒𝐌𝐌 re. clinical trials vs ac……
Source: threadreaderapp.comCategories: General Medicine News, Hem/OncsTweet
RT @Anand_88_Patel: Day 10 - management of asparaginase-related toxicities https://t.co/PIz45kXtda https://t.co/sON31LuL4H